Navigation Links
Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP,Receptor Antagonist at the American College of Cardiology

NEW ORLEANS, March 28, 2007 /PRNewswire/ -- Portola Pharmaceuticals, Inc. presented Phase I data of its ADP receptor antagonist at the of Cardiology's (ACC) 56th Annual Scientific Session this week. Portola's reversible antiplatelet compound, PRT060128, appeared safe and well-tolerated in this study and achieved high-level platelet inhibition.

Portola presented the data in a poster session titled "First in Human Experience with PRT060128, a New Direct-acting, Reversible P2Y(12) Inhibitor for IV and Oral Use" which describes the single ascending dose (SAD) study of the oral formulation of PRT060128. In this study, dose dependent and full inhibition of ADP-induced platelet aggregation was achieved. In addition, following administration of PRT060128, inhibition of platelet aggregation was fully reversed within 24 hours post dosing. All doses of PRT060128 were well tolerated. There were no serious adverse events and no discontinuations due to an adverse event.

"Successful results from both our Phase I oral and intravenous studies build a strong foundation for advancing PRT060128 in the clinic," said Dan Gretler, MD, Portola's vice president of Clinical Development and Regulatory Affairs. "We will initiate our Phase II clinical program later this year to further study the differentiated properties of our ADP receptor antagonist."

Portola's ADP Receptor Antagonist

PRT060128 is an antiplatelet drug that is the only intravenous (IV) and oral ADP receptor antagonist in clinical development. Portola believes that this compound may provide significant clinical benefit through immediate, high-level platelet inhibition in the acute setting and a seamless transition to predictable, reversible platelet inhibition in the chronic setting. Portola has studied this compound in a robust Phase I clinical development program including single ascending dose and multiple ascending dose studies with the oral
'"/>




Page: 1 2

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
3. Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:5/24/2013)...  Heska Corporation (NASDAQ: HSKA, "Heska" or the "Company"), a ... that Dr. Robert Grieve , the Company,s ... , executive vice president and chief financial officer, will ... being held May 30, 2013 in New York ... The Company,s presentation is scheduled to begin at 1:30 ...
(Date:5/24/2013)... 24, 2013  Sinovac Biotech Ltd. (NASDAQ: ... products in China , announced ... of Sinovac, obtained the Certificate of Good Manufacturing ... China State and Food Administration (CFDA) for its ... and its Changping filing and packaging facility. The ...
(Date:5/23/2013)... , May 23, 2013  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... been named the 2013 Life Science Firm of the Year ... (TCM).  Vanda was honored at the TCM,s 25 th ... , Maryland.  The Tech Awards Celebration recognizes the leaders and ... Maryland and the surrounding regions. ...
Breaking Medicine Technology:Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference 2Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 2Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 3Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2
... Aug. 9, 2011 PAREXEL International Corporation (NASDAQ: ... fourth quarter and fiscal year ended June 30, 2011. ... 30, 2011 consolidated service revenue increased by 5.2% to ... year period.  Excluding the positive impact from foreign exchange ...
... The HITECH Act is a law that requires healthcare ... this online data is at the forefront of many leading ... a thought-leader in HIPAA and HITECH compliance, has been asked ... tradeshow during a speaking session on Wednesday, August 10. ...
Cached Medicine Technology:PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 2PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 3PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 4PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 5PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 6PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 7PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 8PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 9PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 10PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 11PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 12PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 13HITECH Act Puts Security of Electronic Medical Records in Hands of Hosting Providers 2
(Date:5/25/2013)... not astonishing that holidays are amongst the most stressful ... family, friends and co-workers. Between the parties to attend, ... parents can afford, parties to arrange, and so much ... and it seems like an eternal cycle of gift ... income can’t catch up to the expenses of these ...
(Date:5/25/2013)... 25, 2013 Communities of Distinction TV ... is the fifth largest media market in the United States ... one visitor destination in Texas and a major convention city. ... American West as it is home to many major museums. ... from sports to the arts. Residents and locals will be ...
(Date:5/25/2013)... great companions for senior citizens, but elderly people who always ... likely to crash than those who never drive with a ... licensed drivers aged 70 and older. The nearly 700 participants ... their pet in the car. Among those who always ... high as among those who never drove with their pet. ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 Providing patients with ... Diet Doc team of weight management professionals. But, aside from ... and effectively, Diet Doc’s hCG diets also provide ... abuse during childhood like bullying, more control over their lives ... of dealing with the underlying factors of weight gain derived ...
(Date:5/25/2013)... 2013 The latest report from ... bowel syndrome (IBS) to bloating, constipation, diarrhea and ... long-lasting, embarrassing, frustrating and difficult health issues to ... health have provided a cure for these ... contributing to digestive health issues, a healthy diet ...
Breaking Medicine News(10 mins):Health News:TheBeautyPlace.com Debuts Their Brand New Beauty Kits 2Health News:Communities of Distinction TV Presents May Air Dates for Dallas-Ft. Worth, Texas 2Health News:Seniors More Likely to Crash When Driving With Pet: Study 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 3Health News:Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org 2
... and Capital Costs, WILMINGTON, Del., Jan. 16 ... for the European auto industry, has signed,a license ... enables auto manufacturers to realize substantial reductions in ... the license agreement, the Cologne-based paint maker will,manufacture ...
... Jan. 16 /PRNewswire-FirstCall/ - DRAXIS Health Inc, (TSX:,DAX) (NASDAQ: ... Stock Exchange,(TSX) for its previously announced Normal Course Issuer ... represent approximately 10%,of the 40,720,539 common shares in the ... 14, 2008, 42,062,538 common shares of DRAXIS were issued ...
... Allowing Pharmacies to Negotiate Collectively Would,Increase Costs by ... Jan. 16 Despite pharmacy benefit,managers, (PBMs) claims ... negotiate with PBMs, would increase costs to,Medicare D ... Congressional,Budget Office (CBO) rejected this bogus number., ...
... Brings 20 Years of Pharmaceutical and CRO Experience ... in Asia/Pacific Region to Key Leadership Role, CINCINNATI, Jan. ... clinical research organization (CRO), today,announced Dr. Ross J. Horsburgh has ... In this role, he will lead the,company,s overall expansion in ...
... It,s often hard for,children on the autism spectrum ... and play time as much as any child. ... ASD children foster friendships at a,Pittsburgh-area conference on ... Center LLC, the conference will feature,author-founder-parent Heather McCracken ...
... (HCC) patients in China may be treated with Traditional ... its effectiveness. These stated that a research group in ... PTEN in HCC, which may suppress tumor cell growth ... research article published on January 7, 2008 in ...
Cached Medicine News:Health News:DuPont Licenses Breakthrough Automotive Coating Technology to German Paint Maker 2Health News:DRAXIS Share Buyback Approved by TSX 2Health News:DRAXIS Share Buyback Approved by TSX 3Health News:DRAXIS Share Buyback Approved by TSX 4Health News:Congressional Budget Office Analysis of HR971 Rejects Pharmacy Benefit Managers' Bogus Claim Bill Would Cost $29 Billion Over 5 Years 2Health News:Kendle Appoints Industry Veteran to Lead Asia/Pacific Expansion 2Health News:Kendle Appoints Industry Veteran to Lead Asia/Pacific Expansion 3Health News:PA Cyber Sponsors Conference on Helping Children With Autism Form Friendships 2Health News:How does Fu-Zheng-Jie-Du-Decoction act on PTEN expression in hepatocellular carcinoma? 2
60 degree angled wedge shaped, round knurled handle, dull finish. For right handed surgeon....
Cross action, round handle, maximum opening 2.8 mm....
Specially designed wider jaws to help split soft nucleus, cross action, round handle, maximum opening 2.8 mm....
Cross action, round handle, maximum opening 2.8 mm....
Medicine Products: